Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Flatiron Health, Exact Sciences Partner on Study of Molecular Residual Disease Test
The collaborators have enrolled their first patient in a prospective clinical study testing a tumor-informed assay for monitoring recurrence across multiple cancers.
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
NeoGenomics, Adaptive Biotech Partner to Offer Combined Blood Cancer Testing
Doctors ordering NeoGenomics Compass test packages will have the option of including Adaptive's ClonoSeq minimal residual disease assay.
Biomarker-Targeted Therapy in 2025: Precise Patient Selection, MRD, Antibody-Drug Conjugates
Premium
The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.
Myriad Genetics, MD Anderson Partner to Study Clinical Utility of MRD Assay
Under the five-year agreement, the partners will assess the clinical utility of Myriad's Precise MRD test in breast, gastrointestinal, genitourinary, and gynecological cancers.